From Nasdaq: 2024-04-14 21:42:31

Nxera Pharma Co. Ltd has partnered with Handok Inc. to distribute PIVLAZ in South Korea. PIVLAZ is the first drug approved in the country for preventing Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage, and will be available in early 2025. Nxera will supply the drug to Handok, who will handle promotion, marketing, sales, and distribution. Nxera will receive an upfront payment and potential milestone payments based on sales.

Overall, this collaboration will bring a new treatment option to patients in South Korea and expand the reach of Nxera Pharma’s products in the region.



Read more at Nasdaq: Nxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South Korea